$PLRX Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Sol...

dough· @semodough · X·2026-04-19 01:33· 2026-04-19评分60

正文

暂无中文译文，显示英文原文。

$PLRX Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 #AACR26 Annual Meeting - Pliant Therapeutics, Inc.

热度 3 · 3 赞 · 0 回复 · 0 转发

会议摘要

CT002NCT06270706按代号 PLN-101095 对上

First-in-human phase I study of PLN-101095, a first-in-class dual αvβ8/αvβ1integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)

Timothy A. Yap, Andrae Vandross, Jenny Amaya-Amaya, Chris N. Barnes, Shuguang Ma, Martin Decaris, Keithryn Nicolas, Alexander Spira, Jacqueline Brown, Patricia LoRusso, Manish R. Sharma

读摘要原文 →

来源：dough · x.com